Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense

Cardamyst FDA approval and launch for PSVT, solid cash, and big expansion upside. Click for more on MIST stock.
NC Biotech

Charlotte’s Milestone Pharmaceuticals gains FDA approval for heart drug

Milestone Pharmaceuticals, a Canadian company with a U.S. subsidiary in Charlotte, is starting the new year with its first ...
Healio

FDA approves self-administered nasal spray for paroxysmal supraventricular tachycardia

Please provide your email address to receive an email when new articles are posted on . The FDA approved a rapid-acting nasal spray for the treatment of acute symptomatic paroxysmal supraventricular ...
Business Insider

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

MONTREAL and CHARLOTTE, N.C., April 08, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of ...
Seeking Alpha

Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet

- Primary endpoint met, with 64.3% of patients who self-administered etripamil converting from supraventricular tachycardia to sinus rhythm within 30 minutes compared to 31.2% on placebo (HR = 2.62, ...
Finanznachrichten

Milestone Pharmaceuticals Inc.: Milestone Receives FDA Approval of CARDAMYST (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal ...

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT ...